MDMDErinGuestErin M. Guest0.000000000000000.00000000000000150Guest, Erin8168551700M.0000-0003-2482-56088163026808Hematology/Oncology PediatricianDr. Guest's research areas of focus are in leukemia in infants, cancer genomics, and cancer predisposition syndromes. She is the study chair for the National Cancer Institute sponsored Children's Oncology Group clinical trial for infants with acute lymphoblastic leukemia (ALL) and she leads the national task force on infant ALL. Dr. Guest collaborates with researchers around the world to discover and develop new, more effective therapies for infants with leukemia.cmhprofilesont:personsuffixperson suffixprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:trainingAtOrganizationeducational organizationprns:trainingLocationtraining locationprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifierbibo:suffixNamename suffixAddressvivo:address1address line 1vivo:address2address line 2vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provinceAgreementvivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:degreeEarneddegree earnedDepartmentvivo:descriptiondescriptionDivisionvivo:educationalTrainingeducation and trainingEducational Trainingvivo:faxNumberfaxGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:majorFieldmajor field of degreevivo:middleNamemiddle name or initialvivo:orcidIdORCID idvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:researchOverviewresearch overviewRolevivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson24288641Thornton KM, Nyp MF, Music Aplenc L, Jones GL, Carpenter SL, Guest EM, Shapiro SM, Manimtim WMCase reports in pediatricsThornton KM, Nyp MF, Music Aplenc L, Jones GL, Carpenter SL, Guest EM, Shapiro SM, Manimtim WM. An unusual case of rapidly progressive hyperbilirubinemia. Case Rep Pediatr. 2013; 2013:284029.Case Rep Pediatr2013-10-29T00:00:002013An unusual case of rapidly progressive hyperbilirubinemia.D015470Disorders81140.899415Leukemia, Myeloid, AcuteMD, MPHAlanGamisAlan S. Gamis0.000000000000000.0000000000000049Gamis, Alan0000-0003-1513-2893Chief, Section of OncologyMDBradleyWaradyBradley A. Warady0.000000000000000.0000000000000063Warady, BradleyDirector, Division of Pediatric Nephrology 3Assistant Professor2Associate Professor1Professor26229553Kingsmore SF, Petrikin J, Willig LK, Guest EGenome medicineKingsmore SF, Petrikin J, Willig LK, Guest E. Emergency medical genomes: a breakthrough application of precision medicine. Genome Med. 2015; 7(1):82.Genome Med2015-07-30T00:00:002015Emergency medical genomes: a breakthrough application of precision medicine.28674028Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis ASBloodGuest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017 08 17; 130(7):943-945.Blood2017-07-03T00:00:002017Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.PhDJohnPerryJohn M. Perry0.000000000000000.00000000000000123Perry, JohnResearch Faculty PhD23DirectorSurgeryMDShawnSt PeterShawn D St Peter0.000000000000000.00000000000000131St Peter, ShawnMedical Chairman D051788Chemicals & Drugs270.988561Myeloid-Lymphoid Leukemia ProteinPhD, MSHung-WenYehHung-Wen Yeh0.000000000000000.00000000000000136Yeh, Hung-Wen0000-0002-9904-3275Research Faculty PhDD054198Disorders21610.928886Precursor Cell Lymphoblastic Leukemia-Lymphoma2401 Gillham RdKansas City MO 64108Kansas City64108MOAuthorship 55894Authorship 56043Authorship 56356Authorship 56803Authorship 57042Authorship 57253Authorship 57355Authorship 57391Authorship 57624Authorship 57711Authorship 58064Authorship 5875120844554Mohan M, Lin C, Guest E, Shilatifard ANature reviews. CancerMohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer. 2010 10; 10(10):721-8.Nat Rev Cancer2010-09-16T00:00:002010Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.21797707Guest EM, Neville KA, Hoyer JD, Safo MK, Garg U, Saunders CJ, Abdulmalik O, Zwick DLHemoglobinGuest EM, Neville KA, Hoyer JD, Safo MK, Garg U, Saunders CJ, Abdulmalik O, Zwick DL. Hb Lake Tapawingo [a46(CE4)Phe?Ser; HBA2:c.140T>C]: a new unstable a chain hemoglobin variant associated with low systemic arterial saturation. Hemoglobin. 2011; 35(4):411-6.Hemoglobin2011-01-01T00:00:002011Hb Lake Tapawingo [a46(CE4)Phe?Ser; HBA2:c.140T>C]: a new unstable a chain hemoglobin variant associated with low systemic arterial saturation.22547686Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S, Marshall S, Florens L, Washburn MP, Shilatifard AMolecular and cellular biologyLuo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S, Marshall S, Florens L, Washburn MP, Shilatifard A. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol Cell Biol. 2012 Jul; 32(13):2608-17.Mol Cell Biol2012-04-30T00:00:002012The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output.25075281Ilboudo CM, Guest EM, Ferguson AM, Garg U, Jackson MAF1000ResearchIlboudo CM, Guest EM, Ferguson AM, Garg U, Jackson MA. Misleading hepatitis B testing in the setting of intravenous immunoglobulin. F1000Res. 2013; 2:249.F1000Res2013-11-18T00:00:002013Misleading hepatitis B testing in the setting of intravenous immunoglobulin.25634704Radhi M, Fulbright JM, Ginn KF, Guest EMPrimary careRadhi M, Fulbright JM, Ginn KF, Guest EM. Childhood cancer for the primary care physician. Prim Care. 2015 Mar; 42(1):43-55.Prim Care2014-11-11T00:00:002014Childhood cancer for the primary care physician.27841777Guest EM, Stam RWCurrent opinion in pediatricsGuest EM, Stam RW. Updates in the biology and therapy for infant acute lymphoblastic leukemia. Curr Opin Pediatr. 2017 02; 29(1):20-26.Curr Opin Pediatr2017-02-01T00:00:002017Updates in the biology and therapy for infant acute lymphoblastic leukemia.28538500Jones GL, McClellan W, Raman S, Sherman A, Guest E, August KJournal of pediatric hematology/oncologyJones GL, McClellan W, Raman S, Sherman A, Guest E, August K. Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2017 07; 39(5):370-375.J Pediatr Hematol Oncol2017-07-01T00:00:002017Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia.30489654DeSimone RA, Myers GD, Guest EM, Shi PAJournal of clinical apheresisDeSimone RA, Myers GD, Guest EM, Shi PA. Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis. J Clin Apher. 2019 Aug; 34(4):487-489.J Clin Apher2018-11-29T00:00:002018Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis.30551569Ahmed AA, Vundamati DS, Farooqi MS, Guest EHigh-throughputAhmed AA, Vundamati DS, Farooqi MS, Guest E. Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects. High Throughput. 2018 Dec 13; 7(4).High Throughput2018-12-13T00:00:002018Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects.1128selected publications3.387850.024439148research areas1.065250.030387410coauthor of53.22563.1556360similar toMDLaurelWilligLaurel K. Willig0.000000000000000.00000000000000154Willig, LaurelMedical Director, Center for Pediatric Genomic Medicine 06/2004University of Oklahoma Norman, OKUniversity of Oklahoma, Medicine MDMedicine07/2007Children's Mercy HospitalKansas City, MOChildren's Mercy Hospital, PediatricsResidencyPediatrics09/2010Children's Mercy HospitalKansas City, MOChildren's Mercy Hospital, Pediatric Hematology/OncologyFellowshipPediatric Hematology/OncologyPathology and Laboratory MedicinePediatricsMedical SchoolResearchClinicalUniversity of Kansas Medical CenterUniversity of Missouri-Kansas CityCo-PIThis translational project is led by Dr. John Perry of Children’s Mercy Research Institute and the specific aims are to identify the pro- vs. anti-cancer cellular immune response to current clinical vs. targeted anthracycline treatment, determine how targeted anthracycline treatment, unlike the clinical dose, eliminates chemoresistant leukemia cells, and define an anti-cancer treatment protocol optimizing anti-tumor immunity while avoiding broad cytotoxicity and resistance.PIThis project is a bedside to bench translation of a novel therapy for infant ALL, testing DNA demethylation in infants treated with azacitidine on the Children’s Oncology Group trial AALL15P1. The project includes a correlative methylation analysis of MLL rearranged leukemia cells in a mouse xenograft model, pre- and post- treatment with azacitidine.PIThe aims of this project are to identify and compare the clonal genomic variants and transcript variants of infant ALL with KMT2A rearrangement at initial diagnosis, relapse, and remission. The goal is to determine the pattern of clonal evolution in infant ALL during treatment.2019-08-30Children's Mercy Cancer Center Auxiliary Research FundErin Guest2017-09-01Identifying biomarkers of relapse in infant acute lymphoblastic leukemia (ALL) through single cell sequencing2021-08-30Braden's Hope FoundationJohn Perry2018-09-01Overcoming therapeutic resistance by repurposing a classic chemotherapeutic drug as targeted therapy to reactivate anti-cancer immunity2019-06-30Noah's Bandage Project FoundationErin Guest2018-06-01Mechanisms of chemotherapy resistance in pediatric acute lymphoblastic leukemia (ALL) with MLL gene rearrangement (MLL-R)Children's Mercy Kansas CityAuthorship 68068Authorship 68652Authorship 69433231571395August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EMPediatric blood & cancerAugust KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer. 2020 01; 67(1):e28021.Pediatr Blood Cancer2019-10-01T00:00:002019Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.31724803August KJ, Guest EM, Lewing K, Hays JA, Gamis ASPediatric blood & cancerAugust KJ, Guest EM, Lewing K, Hays JA, Gamis AS. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatr Blood Cancer. 2020 03; 67(3):e28062.Pediatr Blood Cancer2019-11-14T00:00:002019Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.31969338Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PAClinical cancer research : an official journal of the American Association for Cancer ResearchBurke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307.Clin Cancer Res2020-01-22T00:00:002020Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.PhD, CPONKristinStegengaKristin A. Stegenga0.000000000000000.00000000000000160Stegenga, Kristin0000-0002-3738-9561Nurse ResearcherMD, PhD, FCAPMidhatFarooqiMidhat Farooqi0.000000000000000.00000000000000161Farooqi, Midhat0000-0002-5238-1349Director, Molecular Oncology, Center for Pediatric Genomic MedicinePhD, RN, NEA-BCSusanMcElroySusan F. McElroy0.000000000000000.00000000000000166McElroy, SusanSenior Director, Patient Care Services ResearchMDJoyFulbrightJoy M. Fulbright0.000000000000000.00000000000000175Fulbright, JoyDirector, Adolescent and Young Adult ProgramAuthorship 75643032313104Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, Lu X, Nemechek J, Ruan L, Yu X, Dukes D, Moran A, Pace J, Schroeder K, Zhao M, Venkatraman A, Qian P, Li Z, Hembree M, Paulson A, He Z, Xu D, Tran TH, Deshmukh P, Nguyen CT, Kasi RM, Ryan R, Broward M, Ding S, Guest E, August K, Gamis AS, Godwin A, Sittampalam GS, Weir SJ, Li LNature cell biologyPerry JM, Tao F, Roy A, Lin T, He XC, Chen S, Lu X, Nemechek J, Ruan L, Yu X, Dukes D, Moran A, Pace J, Schroeder K, Zhao M, Venkatraman A, Qian P, Li Z, Hembree M, Paulson A, He Z, Xu D, Tran TH, Deshmukh P, Nguyen CT, Kasi RM, Ryan R, Broward M, Ding S, Guest E, August K, Gamis AS, Godwin A, Sittampalam GS, Weir SJ, Li L. Overcoming Wnt-?-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020 06; 22(6):689-700.Nat Cell Biol2020-04-20T00:00:002020Overcoming Wnt-?-catenin dependent anticancer therapy resistance in leukaemia stem cells.Co-PIThis project is a multi-institutional collaboration between Dr. Guest and Co-PI’s Dr. David Barrett at Children’s Hospital of Philadelphia and Dr. Patrick Brown at Johns Hopkins University. This work will focus on using new and highly detailed single cell sequencing techniques to study KMT2A-rearranged leukemia in infants and the T-cell function profile in the same patients.2023-08-31Department of Defense Peer Reviewed Cancer Research Program, Translational Team Science AwardKathrin Bernt2020-09-01A multi-omics approach to overcome resistance in infant leukemia by identifying immune-therapy failure mechanismsCA190407PhDCraigSmailCraig Smail0.000000000000000.00000000000000187Smail, Craig0000-0001-8045-6021Computational Research FacultyAuthorship 7977332769570Rao K, Farooki S, Guest E, Chastain K, Gener M, Akangire GJournal of pediatric hematology/oncologyRao K, Farooki S, Guest E, Chastain K, Gener M, Akangire G. Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy. J Pediatr Hematol Oncol. 2021 05 01; 43(4):e521-e524.J Pediatr Hematol Oncol2021-05-01T00:00:002021Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy.Co-IThe aims of this project are 1) to validate, annotate, and deposit molecular and clinical data into the National Cancer Institute genomic data repository and 2) to share single cell transcriptomic and epigenomic data of diverse pediatric cancers, including new approaches to analytics, data visualization and intuitive data browsing.2021-08-31NCI Childhood Cancer Data Initiative, Administrative Supplement for the NCI P30 Cancer Center Support GrantMidhat Farooqi2020-09-01Free the Data: Open Sharing of Comprehensive Genomic Childhood Cancer DatasetsMDJayPortnoyJay M. Portnoy0.000000000000000.00000000000000205Portnoy, JayMedical Director, TelemedicineD000970Chemicals & Drugs20570.947703Antineoplastic AgentsD000971Procedures14710.937832Antineoplastic Combined Chemotherapy Protocols34048275Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis ASJournal of clinical oncology : official journal of the American Society of Clinical OncologyPollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 10 01; 39(28):3149-3160.J Clin Oncol2021-05-28T00:00:002021Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.Authorship 99452PIThis project supports next generation sequencing (NGS) of samples from infants enrolled in the COG trial, AALL15P1. The aims are to 1) determine the rate of dominant clone detection by NGS at diagnosis of infant ALL and 2) correlate sequencing-based minimal residual disease with flow cytometry results and event-free survival for infants treated on AALL15P1. The results of this project will impact the design of future trials for infants with ALL.Co-PIThis study is in collaboration with Dr. Jennifer Gerton, Co-PI and Investigator at Stowers Medical Research Institute. The aim is to determine how patterns of centromere instability correlate with relapse and whether copy number instability is a useful biomarker in ALL.2022-06-30Children’s Oncology Group (COG) Hematopoietic Malignancies Integrated Translational Science Center (HM-ITSC) GrantErin Guest2021-07-01Next Generation Sequencing to Detect Minimal Residual Disease in Infant ALL1UG1CA233249-012021-12-31University of Kansas Cancer Center, Cancer Biology Program, Clinical/Basic Science Translational Research Pilot Grant AwardJennifer Gerton2021-01-01Centromeric DNA instability as a biomarker in Acute Lymphoblastic LeukemiaAuthorship 100892234864916Chen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, Gao P, Uzun Y, Fang L, Davenport JW, Hu Y, Zhu Q, Wang K, Libbrecht C, Felmeister A, Rozich I, Ding YY, Hunger SP, Felix CA, Wu H, Brown PA, Guest EM, Barrett DM, Bernt KM, Tan KBloodChen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, Gao P, Uzun Y, Fang L, Davenport JW, Hu Y, Zhu Q, Wang K, Libbrecht C, Felmeister A, Rozich I, Ding YY, Hunger SP, Felix CA, Wu H, Brown PA, Guest EM, Barrett DM, Bernt KM, Tan K. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022 04 07; 139(14):2198-2211.Blood2022-04-07T00:00:002022Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.PIIn this project, our team proposes to genetically engineer human iPS cells to express MLL-Af4. We will then introduce clinically identified genomic variants using CRISPR, differentiate the cells to CD34+ hematopoietic stem cell precursors, and xenograft into immunodeficient mice. We will assess the cells for clonal outgrowth, serial proliferative capacity, cell surface marker expression, latency of onset and morphologic phenotype of leukemia in xenografts.2023-09-30Masonic Cancer Alliance Partners Advisory Board FundErin Guest2021-10-01Evaluating the Impact of Rare, Clinically Detected Germline Variants in MLL-AF4 Leukemia: A Bedside-to-Bench Translational Model of Infant ALLAuthorship 10284135172563Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PAHaematologicaGuest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 05 01; 107(5):1205-1208.Haematologica2022-05-01T00:00:002022Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial.Authorship 105682835580324Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LMBlood advancesMoskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4251-4255.Blood Adv2022-07-26T00:00:002022Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.Authorship 10661531870886McAlpine AK, Sauve LJ, Collet JC, Goldfarb DM, Guest E, McDonald PJ, Zheng A, Srigley JAThe Journal of hospital infectionMcAlpine AK, Sauve LJ, Collet JC, Goldfarb DM, Guest E, McDonald PJ, Zheng A, Srigley JA. Risk factors for cerebrospinal fluid shunt infections during an outbreak: a case-control study. J Hosp Infect. 2020 May; 105(1):78-82.J Hosp Infect2019-12-20T00:00:002019Risk factors for cerebrospinal fluid shunt infections during an outbreak: a case-control study.Authorship 110546Authorship 110931836341281Crow J, Samuel G, Farrow E, Gibson M, Johnston J, Guest E, Miller N, Pei D, Koestler D, Pathak H, Liang X, Mangels C, Godwin AKBiomarker insightsCrow J, Samuel G, Farrow E, Gibson M, Johnston J, Guest E, Miller N, Pei D, Koestler D, Pathak H, Liang X, Mangels C, Godwin AK. MicroRNA Content of Ewing Sarcoma Derived Extracellular Vesicles Leads to Biomarker Potential and Identification of a Previously Undocumented EWS-FLI1 Translocation. Biomark Insights. 2022; 17:11772719221132693.Biomark Insights2022-10-31T00:00:002022MicroRNA Content of Ewing Sarcoma Derived Extracellular Vesicles Leads to Biomarker Potential and Identification of a Previously Undocumented EWS-FLI1 Translocation.36380143Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RSLeukemiaCheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2023 01; 37(1):61-71.Leukemia2022-11-15T00:00:002022Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.Authorship 112661Authorship 1129223Authorship 114131633495140Guest E, Paraskeva N, Griffiths C, Hansen E, Clarke A, Baker E, Harcourt DJournal of plastic, reconstructive & aesthetic surgery : JPRASGuest E, Paraskeva N, Griffiths C, Hansen E, Clarke A, Baker E, Harcourt D. The nature and importance of women's goals for immediate and delayed breast reconstruction. J Plast Reconstr Aesthet Surg. 2021 Sep; 74(9):2169-2175.J Plast Reconstr Aesthet Surg2021-01-09T00:00:002021The nature and importance of women's goals for immediate and delayed breast reconstruction.36725118Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas MThe Lancet. HaematologyGupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141.Lancet Haematol2023-02-01T00:00:002023Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.36996387van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fern?ndez Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Nor?n-Nystr?m U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJLJournal of clinical oncology : official journal of the American Society of Clinical Oncologyvan Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fern?ndez Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Nor?n-Nystr?m U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-M?nster Study Group. J Clin Oncol. 2023 06 01; 41(16):2963-2974.J Clin Oncol2023-03-30T00:00:002023Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-M?nster Study Group.true1Senior Director, Patient Care Services ResearchSenior Director, Patient Care Services Researchtrue1Medical Director, TelemedicineMedical Director, Telemedicinetrue1Medical Director, Center for Pediatric Genomic Medicine Medical Director, Center for Pediatric Genomic Medicine true1Director, Division of Pediatric Nephrology Director, Division of Pediatric Nephrology true1Nurse ResearcherNurse Researchertrue1Research Faculty PhDResearch Faculty PhDAuthorship 115681337259259Faulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PAPediatric blood & cancerFaulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PA. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. Pediatr Blood Cancer. 2023 May 31; e30467.Pediatr Blood Cancer2023-05-31T00:00:002023Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.PIIn this study, we are advancing an exciting new human induced pluripotent stem cell model of pediatric leukemia for use in understanding the distinct roles of major KMT2A rearrangement-associated oncogenic drivers of pediatric leukemia and testing of novel targeted precision therapies.PIThe aims of this proposal are to develop a high content CRISPR screen for modifiers of KMT2A-r in leukemic progression and to identify genetic changes collaborating with KMT2A-r in driving etoposide-mediated therapy related acute myeloid leukemia.2025-12-31Noah's Bandage Project FoundationErin Guest2023-11-01A CRISPR genetic screen in an induced pluripotent stem cell model to discover modifiers of therapy-related pediatric leukemia2026-08-30Braden's Hope FoundationErin Guest2023-09-01Induced pluripotent stem cell models for pediatric KMT2A-r leukemia development and discovery of targeted therapiesPhDLauraRamseyLaura Ramsey0.000000000000000.00000000000000221Ramsey, Laura0000-0001-6417-3961Doctoral Research Facultytrue1Doctoral Research FacultyDoctoral Research FacultyCo-IThis is a multi-institution collaboration, led by Dr. Kathrin Bernt, Children’s Hospital of Philadelphia. The aims are 1) functional and epigenomic predictors of clinical response to venetoclax + induction in infants with newly diagnosed ALL and 2) effect of venetoclax + chemotherapy on T-cells from infants with ALL.Co-PIIn this project, we will characterize and compare pre-treatment immunoglobulin (Ig) rearrangement composition in infants with KMT2A-rearranged (KMT2A-R) and KMT2A-germline (KMT2A-G) B-ALL, and compare high-throughput sequencing with multiparameter flow cytometry for end of induction MRD detection and relapse prediction in infants with B-ALL.2025-12-31St. Baldrick’s Foundation - American Cancer Society; Childhood Cancer Research RFA: Pilot Accelerator AwardKathrin Bernt2024-01-01Venetoclax for infant ALL – COG AALL23212025-10-31Alex’s Lemonade Stand Reach GrantCarol Fries2023-11-10Refining risk stratification for infants with KMT2A-rearranged and KMT2A-germline B-ALL by immunoglobulin high-throughput sequencing analysis of patients enrolled on COG clinical trial AALL15P1PhDBrookeFridleyBrooke Fridley0.000000000000000.00000000000000222Fridley, BrookeDirector, Biostatistics and Epidemiology Coretrue1Director, Biostatistics and Epidemiology CoreDirector, Biostatistics and Epidemiology Coretrue1Director, Molecular Oncology, Center for Pediatric Genomic MedicineDirector, Molecular Oncology, Center for Pediatric Genomic Medicinetrue1Chief, Section of OncologyChief, Section of Oncologytrue1Computational Research FacultyComputational Research Facultytrue1Director, Adolescent and Young Adult ProgramDirector, Adolescent and Young Adult Programtrue1Research Faculty PhDResearch Faculty PhDtrue1Hematology/Oncology PediatricianHematology/Oncology Pediatrician2Director, Cancer Genomics ProgramDirector, Cancer Genomics Program3Director, Cancer Center BiorepositoryDirector, Cancer Center Biorepository4ProfessorProfessor5Research Assistant Professor of PediatricsResearch Assistant Professor of Pediatricstrue1Medical Chairman Medical Chairman